Integer Holdings Conference Call Summary Company Overview - **Company**: Integer Holdings (NYSE: ITGR) - **Date**: March 18, 2026 - **Participants**: Payman Khales (CEO), Diron Smith (CFO), Kristen Stewart (Investor Relations) Key Points Management Transition - The transition to the new CEO has been smooth, with a strong foundation and strategy in place [3][4] - Focus areas include customer success, operational excellence, and talent development [4] Board of Directors and Governance - A cooperation agreement was reached with Irenic Capital Management, resulting in the addition of two new board members [6][7] - The board refreshment process has been ongoing, with five new members added in the last five years [6] 2026 Guidance and Market Performance - 2026 is viewed as a transition year with expected headwinds from three products that had strong growth in 2025 but are not meeting adoption expectations [10][11] - These three products contributed just under 6% of total revenues in 2025, but are expected to drop below 2% in 2026, resulting in a headwind of 300-400 basis points [13][14] - The underlying business is expected to grow at a rate of 4%-6% excluding the impact of these products [10][22] Market Growth Expectations - The company anticipates a return to market growth in the second half of 2026, with expectations of achieving 200 basis points above market growth in 2027 [12][26] - The growth rate is supported by a strong pipeline and new product launches in faster-growing markets such as neurovascular, structural heart, and electrophysiology [16][18] Margin and Cost Management - Operating margins are expected to experience pressure in Q1 2026 due to fixed cost deleveraging but are projected to improve throughout the year [28][29] - The company is focused on disciplined cost management and expects to leverage fixed costs as sales grow [28][30] Input Cost Volatility - The company does not foresee significant impacts from recent volatility in input costs, as a large portion of the supply base is in the US and there are price protections in place [32][34] Long-term Financial Objectives - Strategic financial objectives remain unchanged: to grow sales 200 basis points above market and to grow operating income at twice the rate of sales growth [36][37] Product Development and Pipeline - Product development sales have quadrupled since 2017, indicating a strong pipeline and customer relationships [50][51] - The PMA product portfolio is expected to grow at a CAGR of 15%-20% over the next 3-5 years [53] Capacity Expansion - The company is strategically expanding its capacity to avoid constraints on growth, with recent expansions in facilities in Ireland and Virginia [55][56] Market Positioning - Integer is well-positioned in the electrophysiology market, with a broad portfolio and strong pipeline [39][40] - Neuromodulation is expected to grow at a high single-digit rate, with various therapies addressing multiple conditions [61][62] Future Growth Opportunities - Renal denervation is viewed as a potential long-term growth opportunity, leveraging existing capabilities in electrophysiology [64] Conclusion - Integer Holdings is navigating through a transition year with temporary headwinds but remains optimistic about returning to growth in the latter half of 2026 and achieving above-market performance in 2027 and beyond [67]

Core Insights - DaVita Inc. experienced a significant stock rally in February, with a 43% increase, following a strong quarterly report after a challenging year in 2025 where the stock was down 24% [1] - The company is recognized for its kidney dialysis machines and provides treatment through various channels including outpatient centers, hospitals, and home-based care [3] Group 1 - DaVita was the third-best performer in the S&P 500 in February, indicating a recovery in investor sentiment [1] - Analysts and investors had previously adopted a negative outlook on DaVita, which contributed to the stock's poor performance in 2025 [1] - The recent quarterly performance exceeded expectations, leading to a surge in stock price as the market adjusted its perception of the company's prospects [1]

Financial Data and Key Metrics Changes - The company reported Q4 sales of $2 billion, reflecting a 3.5% increase on an organic basis but a 3.7% decline on a reported basis due to the impact of the Purification & Filtration (P&F) divestiture [18][19] - Gross margins were 53.5%, a sequential reduction of 230 basis points, primarily due to higher logistics costs and manufacturing performance timing [20] - Adjusted operating income was $397 million, resulting in an operating margin of 19.9%, which was below expectations due to gross margin headwinds [21] - The company ended the quarter with nearly $900 million in cash and equivalents and net debt of $4.2 billion, including the funding for the Acera acquisition [22] Business Line Data and Key Metrics Changes - MedSurg segment delivered $1.2 billion in sales, a 3.2% organic growth, with advanced wound care growing 1.7% [19] - Dental Solutions segment achieved $343 million in sales, a 5.9% organic growth, driven by core restoratives and back order improvements [19][11] - Health Information Systems (HIS) segment contributed $348 million in sales, a 3.2% organic growth, supported by revenue cycle management software solutions [20] Market Data and Key Metrics Changes - The company noted that the dental market is stable to slightly improving, with expectations for continued growth driven by new product development [57] - The advanced wound care market, including the Acera acquisition, is in a $1 billion market growing at 10% [72] Company Strategy and Development Direction - The company has prioritized five growth drivers expected to deliver over 80% of future growth, focusing on portfolio optimization and strategic acquisitions [4][8] - The Transform for the Future program aims to capture operational efficiencies and support margin expansion while investing for growth [63][66] - The company plans to continue evaluating attractive assets for acquisition and assessing current assets for future fit [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving long-range revenue targets faster than expected, despite external headwinds [5] - The company anticipates organic sales growth of 2%-3% for 2026, with a potential contribution from the Acera acquisition [25] - Management highlighted the importance of AI as an opportunity rather than a threat, particularly in autonomous coding [39] Other Important Information - The company announced a $1 billion share repurchase program, which began execution in January [8] - The effective tax rate for the quarter was 16.6%, benefiting from an end-of-year release of tax reserves [22] Q&A Session Summary Question: Margins and 2026 Guidance - Management noted that approximately 150 basis points of the cost in Q4 gross margins was one-time in nature, with a normalized gross margin expected around 55% [31] - For 2026, management plans to expand operating margins by 50 to 100 basis points despite tariff headwinds [32][33] Question: AI in Healthcare IT - Management views AI as an opportunity to enhance autonomous coding, leveraging proprietary algorithms and vast data sets [39] Question: Dental Segment Performance - Growth in the dental segment was primarily driven by new product launches and back order recovery, with expectations for stable market conditions going forward [56][57] Question: Acera Acquisition Expectations - The Acera acquisition is expected to contribute significantly to advanced wound care growth, with a healthy double-digit growth outlook [72]

Summary of Baxter International 2026 Conference Call Company Overview - **Company**: Baxter International (NYSE: BAX) - **Date of Conference**: February 26, 2026 Key Industry Insights - **Medtech Fundamentals**: The underlying fundamentals of the medtech industry are described as solid and stable, despite stock performance concerns. Patient volumes and procedure volumes are in a decent place, with no significant hyperinflationary pressures noted [12][13]. - **IV Solutions Market**: Demand for IV solutions has decreased by approximately 10-15% from pre-hurricane levels, establishing a new baseline for the market. This decline is attributed to changes in clinical practices following a hurricane [13][14][41]. Company-Specific Developments - **Leadership Changes**: The arrival of a new CEO, Andrew, is seen as timely for Baxter, allowing the company to build on a clearer operational foundation after recent distractions from divestitures [20][21]. - **Operational Model**: The introduction of a new operating model (GPS) aims to enhance consistency in operations and performance tracking. This model is expected to lead to improved operational predictability [22]. - **Verticalization Strategy**: Baxter is evolving its business structure to allow for end-to-end ownership of profit and loss (P&L), moving away from a country-led structure. This change is intended to streamline decision-making and improve accountability [29][30][37]. Financial Performance and Guidance - **2026 Guidance**: The guidance for 2026 is described as prudent, factoring in challenges and opportunities. It does not include any sales from the Novum product, which is under a voluntary shipping hold [101][103]. - **Margin Expectations**: The company anticipates sequential improvement in gross and operating margins throughout 2026, particularly in the second half of the year, as operational issues are resolved [116][118]. - **Capital Allocation**: Baxter is focused on deleveraging its balance sheet, targeting a debt-to-EBITDA ratio of three times by the end of the year. Internal investments in R&D and capital spending remain a priority [131][134]. Product Innovations - **New Products**: The Connex 360, a next-generation monitoring device, and the Dynamo, a connected stretcher, are highlighted as key innovations expected to drive growth in 2026. Customer feedback has been positive for these products [76][78]. Challenges and Risks - **Supply Chain Issues**: The company has faced supply challenges in its pharmaceutical business, which have impacted production and market performance. These issues are expected to improve in the second half of 2026 [47][110]. - **Tariff Changes**: Uncertainty surrounding tariff changes is acknowledged, with ongoing efforts to assess their impact on the business [99][100]. Conclusion - Baxter International is positioned at a pivotal point, focusing on stabilizing operations, improving financial performance, and driving innovation. The company aims to build credibility with stakeholders through consistent execution and strategic growth initiatives as it moves into 2026 [145][151].

Financial Data and Key Metrics Changes - For the full year 2025, the company reported net sales of $701 million, exceeding the revised guidance range, and generated adjusted diluted earnings per share of $0.94 [4][11] - The adjusted EBITDA for the year was $87 million, with an adjusted gross margin of 54.6% and adjusted SG&A as a percentage of revenue of 42% [12][19] - For Q4 2025, net sales were approximately $181 million, with adjusted diluted earnings per share of $0.29 and adjusted EBITDA of $28 million [11][19] Business Line Data and Key Metrics Changes - The Specialty Nutrition Systems portfolio grew over 8% organically compared to the prior year, driven by strong demand in long-term and short-term enteral feeding products [6][15] - The Pain Management & Recovery portfolio saw normalized organic sales increase by 2.3%, with the radiofrequency ablation business posting double-digit organic growth [7][18] - The Game Ready portfolio experienced a slight decline year-over-year but maintained similar revenue levels throughout 2025 [9][18] Market Data and Key Metrics Changes - The Specialty Nutrition Systems segment's operating profit was 19%, down 100 basis points from the previous year due to unfavorable tariff impacts [17] - The Pain Management & Recovery segment's operating profit improved by 270 basis points to 4%, reflecting effective cost management despite tariff costs [18] - The hyaluronic acid injections and IV therapy product lines reported a decline of over 35% compared to the prior year due to the divestiture of the HA business [19] Company Strategy and Development Direction - The company is focused on five strategic imperatives: accelerating organic growth, managing tariff impacts, realizing operating efficiencies, improving or divesting underperforming assets, and acquiring synergistic businesses [10][23] - The company is executing a China exit strategy, aiming to have all syringe manufacturing operations out of China by June 2026 [12][21] - The integration of Nexus Medical into the neonatal portfolio is progressing well, with expectations for double-digit growth in 2026 [13][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for continued growth in 2026, despite anticipated tariff impacts [20][23] - The company expects net sales in the range of $700 million to $720 million for 2026, with mid to high single-digit growth in the Specialty Nutrition Systems segment [21] - Management highlighted the importance of ongoing tariff mitigation strategies and the expected improvement in gross margins in the second half of 2026 [20][34] Other Important Information - The company generated $43 million of free cash flow for the full year, higher than anticipated due to timing of one-time cash charges [19][20] - Capital expenditures for 2026 are expected to be around $25 million, slightly lower than 2025, to support the accelerated China exit plan [22] Q&A Session Summary Question: Insights on tariffs and 2026 outlook - Management estimated a $30 million impact from tariffs in 2026, with a significant portion related to China [27][29] - The company is confident in exiting China by June and delivering products from Mexico and Cambodia [28][30] Question: Revenue guidance and organic growth rates - The consolidated organic growth rate is expected to be around 5%, with mid to high single digits for Specialty Nutrition Systems and low to mid single digits for Pain Management & Recovery [36][37] Question: Operating leverage and cost-saving initiatives - Management expressed high confidence in continuing to drive efficiency in 2026, with a focus on both R&D and SG&A [38][39] - Cost containment measures are expected to offset additional tariff expenses and support earnings expansion [41] Question: Specialty Nutrition performance and Nexus acquisition - Demand for the Specialty Nutrition Systems portfolio remains high, with Nexus performing better than expected and contributing to growth [42][44]

Core Viewpoint - Tempus AI has launched a new HRD-RNA cancer detection algorithm that provides real-time assessment of tumor functional status by analyzing gene expression rather than structural DNA damage [1] Group 1: Technology and Methodology - The HRD-RNA approach allows for the detection of HRD in patients and cancer types where genomic scars are difficult to identify [1] - This method differs from traditional DNA testing, focusing on RNA analysis to evaluate cancer [1] Group 2: Clinical Implications - A real-world validation study indicates that HRD-RNA positive metastatic pancreatic cancer patients receiving first-line platinum-based therapy have a significantly lower risk of death compared to those receiving non-platinum first-line treatment [1] - Complete supporting data for this study is expected to be published later this year [1]

Core Viewpoint - Tempus AI has launched a new HRD-RNA cancer detection algorithm, which offers real-time assessment of tumor functional status by analyzing gene expression rather than structural DNA damage, marking a significant advancement over traditional DNA testing methods [1] Company Summary - Tempus AI's stock rose over 7%, reaching $56.31 following the announcement of the new HRD-RNA cancer detection algorithm [1] - The new RNA-based approach allows for the detection of HRD in patients and cancer types where genomic scars are difficult to identify [1]

Group 1 - Major stock indices are experiencing declines, with Dow futures down 0.10%, S&P 500 futures down 0.27%, and Nasdaq futures down 0.59% [1] - Gold mining stocks are trading lower ahead of the market opening, with Harmony Gold down 4.2%, Newmont down 3%, Sibanye Stillwater down 5.8%, and Barrick Gold down 2.4% [1] - AI application stocks are also down, with SAP SE falling nearly 3%, AppLovin down over 2%, and Palantir and Snowflake both down over 1% [1] - Chinese concept stocks are seeing gains before the market opens, with Alibaba up 0.80%, Pinduoduo up 0.53%, NetEase up 0.19%, Baidu up 1.45%, and JD.com up 0.29% [1] - Spot gold briefly fell below $4900, trading down 1.40% at $4922.2 per ounce, while spot silver dropped over 4%, down 2.32% at $74.6 per ounce [1] Group 2 - SpaceX and its subsidiary xAI are reportedly participating in a highly classified Pentagon bidding process aimed at developing voice-controlled autonomous drone swarm technology [2] - Elon Musk announced that the Cybercab, which will not have pedals or a steering wheel, is set to begin production in April [2] - Apple has announced a significant upgrade for Apple Podcasts, introducing video podcast functionality this spring to enhance its presence in the video podcasting space [2] - Danaher is nearing a deal to acquire medical technology company Masimo for approximately $10 billion [2]

Core Viewpoint - Baxter International Inc. experienced a significant stock price drop of 14% following the release of its fourth-quarter earnings, which fell short of analyst expectations, along with a disappointing full-year profit guidance [1][3]. Financial Performance - The company reported an adjusted earnings per share of $0.44, which was below the analyst expectation of $0.54 [3]. - Revenue reached $2.97 billion, exceeding the analyst consensus of $2.84 billion, and showed an 8% year-over-year growth on a reported basis (3% growth on an operational basis) [3]. - Despite the revenue exceeding expectations, concerns over profitability overshadowed the positive sales performance [3]. - For the fiscal year 2026, the company projected adjusted earnings per share between $1.85 and $2.05, significantly lower than the analyst consensus of $2.25 [3]. Business Segments - By business segment, sales in medical products and therapies grew by 6% to $1.39 billion, medical systems and technologies increased by 5% to $827 million, and the pharmaceutical business rose by 4% to $668 million [4]. Organizational Changes - Baxter introduced a new operational model aimed at simplifying its organizational structure and enhancing performance [4]. - The company announced changes to its board, appointing Michael R. McDonnell as a new director, while Cathy R. Smith and Stephen H. Rusckowski are set to resign on February 13, 2026 [4].

Core Insights - The introduction of AI-assisted screening in breast cancer detection significantly improves screening efficacy and reduces the incidence of interval cancers, which are diagnosed between scheduled screenings [1][2] Group 1: Research Findings - The study involved approximately 106,000 Swedish women aged 40 to 74, with a follow-up period of over two years [1] - AI-assisted screening reduced the workload for radiologists by 44% and increased breast cancer detection rates by 29% compared to traditional methods [1] - The incidence of interval cancers in the AI-assisted group decreased by 12% compared to the control group, with a lower proportion of more severe cases among the remaining interval cancers [1] Group 2: Clinical Implications - AI assistance not only enhances the sensitivity of screenings, making it less likely to miss cancers, but it also does not increase the rate of false positives, which can lead to unnecessary anxiety and medical costs [2] - The results support the safety, accuracy, and efficiency of AI-assisted breast screening in clinical applications, with the technology already being implemented in some regions of Sweden and other parts of Europe [2]